Assessment of oral famotidine in preventing hypersensitivity reactions in patients receiving taxanes and platinum
Phase 3
Recruiting
- Conditions
- patient receiving taxanes and platinum-based anticancer agents.
- Registration Number
- IRCT20160310026998N13
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
receiving taxanes and platinum based anticancer agents
Exclusion Criteria
Having a history of drug allergies
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduce the incidence of hypersensitivity reactions. Timepoint: Up to 2 hours after chemotherapy and 1 month later. Method of measurement: observation.
- Secondary Outcome Measures
Name Time Method Reducing any need to reduce the dose or discontinue chemotherapy following the patient's intolerance to the hypersensitivity reaction. Timepoint: 2 hours after chemotherapy and 1 week later. Method of measurement: observation.